Zobrazeno 1 - 8
of 8
pro vyhledávání: '"59"'
Autor:
Anna Maria Storniolo, Aditya Bardia, Cesar A. Santa-Maria, Vered Stearns, Claire F. Snyder, Antonio C. Wolff, Stacie Jeter, Anne Nguyen, Shannon Slater, Daniel F. Hayes, John H. Fetting, Katie Quinlan, Robert S. Miller, Roisin M. Connolly, Nora Lynn Henry, Gary L. Rosner, Jane Zorzi, Amanda L. Blackford
Publikováno v:
Breast cancer research and treatment. 171(1)
PURPOSE: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced
Autor:
Mateusz Opyrchal, Matthew P. Goetz, Antonino B. D'Assoro, Tufia C. Haddad, Minetta C. Liu, Vera J. Suman, James N. Ingle, Prema P. Peethambaram
Publikováno v:
Breast Cancer Research and Treatment
Purpose In estrogen receptor-positive (ER+) breast cancer models, activation of Aurora A kinase (AURKA) is associated with downregulation of ERα expression and resistance to endocrine therapy. Alisertib is an oral selective inhibitor of AURKA. The p
Autor:
Britta Weigelt, Anne Pavlick, C. Kent Osborne, Marilyn M. Li, Kathleen A. Burke, Jorge S. Reis-Filho, Tao Wang, Fresia Pareja, Matthew P. Goetz, Rachel Schiff, Jenny C. Chang, Rita Nanda, Suzanne A. W. Fuqua, Carmine De Angelis, Ian E. Krop, Ingrid A. Mayer, Mothaffar F. Rimawi, Sabrina Herrera, Antonio C. Wolff, Andres Forero, Felipe C Geyer, Alejandro Contreras, Susan G. Hilsenbeck, Carolina Gutierrez
Publikováno v:
Breast Cancer Research and Treatment. 167:731-740
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in
Autor:
Roy B Mukku, Anthony F. Yu, Kevin C. Oeffinger, Richard M. Steingart, Jennifer E. Liu, Chau T. Dang, Shivani Verma, Clifford A. Hudis
Publikováno v:
Breast Cancer Research and Treatment. 166:241-247
Trastuzumab improves overall survival for women with HER2-positive breast cancer but is associated with cardiotoxicity, especially when administered after anthracyclines. Use of non-anthracycline trastuzumab-based regimens is rising, particularly for
Autor:
Brooke R. Daniel, Sharon A. Goble, Mark Keaton, Yvonne Manalo, Linda D. Bosserman, Denise A. Yardley, Martin J. Bury, David Drosick, Victor M. Priego, Howard A. Burris, Donald S. Gravenor, Robyn R. Young, Adam Brufsky, Fred J. Kudrik, Janice F. Eakle, William N. Harwin, Caryn Silver, Roger Inhorn, Jeffrey A. Bubis, John D. Hainsworth, Gladys Rodriguez, Edward Arrowsmith, Kelly Pendergrass
Publikováno v:
Breast Cancer Research and Treatment. 164:649-658
Ixabepilone is a microtubule stabilizer with activity in taxane-refractory metastatic breast cancer and low susceptibility to taxane-resistance mechanisms including multidrug-resistant phenotypes and high β-III tubulin expression. Since these resist
Autor:
William E. Barlow, S. Chennuru, Daniel F. Hayes, Julie R. Gralow, Anne F. Schott, S. W. Corso, Robert B. Livingston, Gabriel N. Hortobagyi, E. A. Perez, Danika Lew, Hamid R. Mirshahidi, William M. Sikov, Zeina Nahleh, Lajos Pusztai
Publikováno v:
Breast Cancer Research and Treatment
SWOG S0800, a randomized open-label Phase II clinical trial, compared the combination of weekly nab-paclitaxel and bevacizumab followed by dose-dense doxorubicin and cyclophosphamide (AC) with nab-paclitaxel followed or preceded by AC as neoadjuvant
Publikováno v:
Breast cancer research and treatment. 155(1)
To examine the relationship between local recurrence and breast cancer mortality in women with early-stage breast cancer. We studied 1675 women with stage 0 (DCIS), stage I or stage II breast cancer who were treated with breast-conserving surgery at
Autor:
William E. Barlow, Stanley Vogel, Kristine Rinn, Kim Z Dammann, Danika Lew, Gabriel N. Hortobagyi, Julie R. Gralow, Robert B. Livingston, George Somlo, Lucas Wong
Publikováno v:
Breast Cancer Research and Treatment
Docetaxel and vinorelbine have demonstrated Single-agent activity in breast cancer. Preclinical studies suggest potential synergy between these antitubulin chemotherapy agents. This study evaluates these drugs in combination in metastatic breast canc